伊克力西斯 EXEL 深 沪
已收盘 09-19 16:00:00 美东时间
26.83
+0.010
+0.04%
华盛通- 最 高27.10
- 今 开26.90
- 成交量 244.06万股
- 最 低 26.65
- 昨 收 26.82
- 总市值 81.29亿
- 52周最高 27.83
- 市盈率 静 41.51
- 换手率 0.81%
- 52周最低 18.64
- 委 比 69.88%
- 总股本 3.03亿
- 历史最高 32.50
- 量 比 1.48
- 振 幅 1.68%
- 历史最低 1.26
- 每 手 1
- 风险率 1.68%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多A Closer Look at 5 Analyst Recommendations For Exelixis
Exelixis (NASDAQ:EXEL) underwent analysis by 5 analysts in the last quarter, re...
09-18 20:01
Expert Outlook: Exelixis Through The Eyes Of 5 Analysts
Exelixis (NASDAQ:EXEL) has been analyzed by 5 analysts in the last three months...
08-09 03:06
快讯 | Exelixis公司：H.c.温莱特将目标价从28美元提高到29美元
Exelixis, Inc. : H.c. Wainwright Raises Target Price to $29 From $28
08-08 18:12
Analyst Sees Exelixis At Inflection Point Despite Mixed Trial Results
Exelixis reports strong Q2 earnings with adjusted EPS of $0.84, surpassing estimates. The CONTACT-02 trial for mCRPC showed significant PFS benefit but OS did not achieve statistical significance. Exelixis plans to submit a supplemental FDA application in 2024.
08-08 02:15
RBC Capital Reiterates Outperform on Exelixis, Maintains $27 Price Target
RBC Capital analyst Gregory Renza reiterates Exelixis (NASDAQ:EXEL) with a Outperform and maintains $27 price target.
08-08 00:17
Exelixis: A Strong Buy on Robust Cabozantinib Sales and Favorable Litigation Outlook
Analyst Silvan Tuerkcan from JMP Securities maintained a Buy rating on Exelixis...
08-07 12:45
快讯 | Exelixis公司：Leerink Partners将目标价从19美元提高至25美元
Exelixis Inc : Leerink Partners Raises Target Price to $25 From $19
08-07 11:11
快讯 | 伊克力西斯预计全年总营收为19.75亿美元至20.75亿美元。
Exelixis Sees FY Total Revenues $1.975 Bln - $2.075 Bln
08-07 04:48
快讯 | Exelixis公司：从艾普森获得了基于可博盐酸盐销售的1.5亿美元里程碑款项
Exelixis Inc: Earned $150 Mln Cabozantinib Sales-Based Milestone From Ipsen
08-07 04:48
快讯 | Exelixis公司预计2024年每股收益为1.12美元，收入为18.8亿美元 - LSEG IBES数据
Exelixis Inc FY2024 Shr View $1.12, Rev View $1.88 Bln -- LSEG IBES Data
08-07 04:48
